R&D | April 15, 2026
Regeneron and Telix strike major radiopharma pact in push into next-gen cancer therapies
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets
Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
IntraSight Plus enables confident decision-making and better patient care,” Philips said, emphasizing efficiency, simplicity, and precision
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Designed for intense clinical environments, Rembra can handle up to 270 exams per day
The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
Subscribe To Our Newsletter & Stay Updated
